There was no significant difference in the rate of breast cancer in FIT : 1.5 % ( n = 46 ) in the placebo group and 1.8 % ( n = 57 ) in the alendronate group ( hazard ratio [ HR ] , 1.24 [ 95 % CI , 0.84-1 .83 ] ) .